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Abstract
Despite the wide consumption of coffee, its anti-inflammatory effect on clinical severity of psoriasis is still debatable. The 
aim of this study was to evaluate the association between the coffee consumption and clinical severity of psoriasis in a 
sample of patients stratified according to the presence of the metabolic syndrome (MetS) and smoking. This cross-sectional 
case–control observational study was conducted on 221 treatment-naïve psoriatic patients. Lifestyle habits, anthropometric 
measures, clinical and biochemical evaluations were obtained. Clinical severity of psoriasis was assessed by Psoriasis Area 
and Severity Index (PASI) score. Data on energy caloric intake and coffee consumption were collected using a 7-day food 
diary record. The coffee consumption was analyzed as coffee intake (consumers and non-consumers) and daily servings 
(range 0–4 servings/day). Coffee consumers have a lower PASI score vs non-consumers (p < 0.001). The lowest PASI score 
and MetS prevalence were found in patients consuming 3 cups of coffee/day (p < 0.001), which was also the most common 
daily serving (34.8%), whereas the highest PASI score was found among those drinking ≥ 4 cups/day. Grouping the case 
patients according to smoking and MetS, the best odds of PASI score was observed in those drinking 3 cups of coffee per 
day and no smokers, after adjusting for total energy intake (OR 74.8; p < 0.001). As a novel finding, we reported a negative 
association between coffee intake, MetS prevalence and clinical severity of psoriasis. The evaluation of the anti-inflammatory 
effect of coffee on clinical severity of psoriasis, whose metabolic risk increases along with its clinical severity, could be of 
great importance from a public health perspective.
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Introduction
Coffee is one the most consumed beverage in the World, 
just after water and tea (Ludwig et al. 2014). It is estimated 
that the coffee consumption worldwide is about 50 million 
cups; in particular, per capita consumption for Italy, where 
coffee is almost prepared and consumed in the Italian style 
(i.e., by espresso or moka), is 5.6 kg (International Coffee 
Council 2017). Long-term intake of coffee, whose most 
basic component is caffeine, has demonstrated to exert a 
number of potential benefits on human health (Grosso et al. 
2017; Tajik et al. 2017; Hall et al. 2015), through its effects 
on different systems, including the immune system (Gökcen 
and Şanlier 2017; Sharif et al. 2017). Coffee consumption 
has reported to have pronounced antioxidant activity, result-
ing in a decreased inflammatory state (Li et al. 2012), due to 
the powerful anti-oxidants such as polyphenols containing 
chlorogenic acid and caffeic acid, diterpenes comprising caf-
estol and kahweol, lactones, niacin, and trigonelline, which 
is the precursor of niacin (Baspinar et al. 2017). Long-term 
intake of coffee reduces the activation in vitro Nuclear Fac-
tor Kappa B (NF-κB) (Shin et al. 2017). NF-κB is a family 
of transcription factors controlling apoptosis and pro-inflam-
matory cytokine expression, in a dose-dependent manner, 
via the inhibition of the oxidative stress due to reactive oxy-
gen species (ROS) accumulation (Chu et al. 2013; Akash 
et al. 2014; Khan et al. 2016). Although several studies have 
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been conducted to elucidate the effects of coffee consump-
tion on various diseases, it has also been reported that cof-
fee consumption could prevent several inflammation-driven, 
chronic diseases, including cardiovascular diseases (Mon-
tagnana et al. 2012), type 2 diabetes (Bae et al. 2014; Floegel 
et al. 2012), neurodegenerative diseases such as Parkinson’s 
and Alzheimer’s diseases (Madeira et al. 2017), non-alco-
holic fatty liver disease and its progression to hepatic fibrosis 
and cirrhosis (Liu et al. 2015; Wijarnpreecha et al. 2017). In 
addition, growing interest has been focused on the inverse 
association of coffee consumption with the Metabolic Syn-
drome (MetS) (Baspinar et al. 2017).
Psoriasis is a chronic immune-mediated inflammatory 
skin disease. Psoriasis lesions are characterized by hyper-
proliferation of epidermal keratinocytes associated with 
inflammatory cellular infiltrate in both dermis and epidermis 
(Barrea et al. 2017). Of interest is that psoriasis is associated 
with an increased metabolic risk in a manner that varies 
with the severity of psoriasis (Ganzetti et al. 2016; Gisondi 
et al. 2015), as well as with non-alcoholic fatty liver dis-
ease (Balato et al. 2015a). According to recent literature 
data, psoriatic patients show a greater prevalence of obesity 
(Fleming et al. 2015) and MetS (Voiculescu et al. 2014), 
which confers a higher cardiovascular risk (Shahwan and 
Kimball 2015). Among the environmental risk factors for 
psoriasis, evidence is accumulating that nutrition plays a 
major role per se in the pathogenesis of psoriasis (Barrea 
et al. 2016a). In particular, specific nutrients, such as mono-
unsaturated fatty acids, omega 3 (Guida et al. 2014), and 
vitamin D (Barrea et al. 2017), or healthy dietary patterns, 
such as the Mediterranean diet (Barrea et al. 2015a), could 
contribute to reduce the clinical severity of psoriasis, also 
adjusting for known confounders, such as body weight and 
MetS (Barrea et al. 2015b). The association of circulating 
vitamin D levels with chronic autoimmune diseases (Altieri 
et al. 2017) and clinical psoriasis severity has been largely 
reported (Lee and Song 2018). In addition, specific param-
eters of body composition commonly used as expression of 
the nutritional status, such as phase angle, are associated 
with the clinical severity of psoriasis (Barrea et al. 2016b).
Considering the evidence linking coffee consumption and 
inflammation, the anti-inflammatory effect of coffee could be 
relevant in the pathogenesis of psoriasis. However, only few 
studies investigated the association between coffee consump-
tion and psoriasis and there is still considerable uncertainty, 
especially regarding its possible contribution to the clinical 
severity of psoriasis (Sharif et al. 2017). On the one side, in 
a cohort study on 968 subjects, there was no evidence for the 
association between consumption of coffee and incidence of 
psoriasis (Li et al. 2012). This lack of association was also 
confirmed in a case–control study on 94 twins pairs (Duffy 
et al. 1993). On the other side, both in vivo and in vitro stud-
ies supported the anti-inflammatory and immunosuppressant 
activities of coffee in psoriasis (Gökcen and Şanlier 2017; 
Swanson et al. 2007; Li et al. 2012). In particular, Swanson 
et al. (2007) demonstrated in an observational study con-
ducted on 65 psoriatic patients that coffee consumption did 
not aggravate this pathological condition (Swanson et al. 
2007), while Li et al. (2012) found that coffee improved the 
efficacy of psoriasis pharmacological treatments, such as 
methotrexate and sulfasalazine (Li et al. 2012). However, it 
is important to remember that smoking per se may increase 
the risk of psoriasis (Setty et al. 2007), and could represent 
the major confounder underlying the association between 
coffee intake and risk of psoriasis in age-adjusted models (Li 
et al. 2012). Indeed, it is well-known that cigarette smoking 
and coffee consumption are strongly associated (Swanson 
et al. 1994; Hewlett and Smith 2006; Ware et al. 2017), and 
several observational studies showed that coffee consumers 
are more likely to be smokers than non-consumers (Hewlett 
and Smith 2006; Ware et al. 2017; Freedman et al. 2012).
Besides the association between coffee and presence/
absence of psoriasis, data supporting this association based 
on a more detailed coffee consumption and the clinical 
severity of psoriasis are still lacking. In addition, no stud-
ies have investigated the association between coffee con-
sumption and MetS in the clinical setting of psoriasis, in 
particular considering the confounding effect of cigarette 
smoking. The aim of this observational study was to evalu-
ate the association between coffee consumption and clinical 
severity of psoriasis in a sample of treatment-naïve psoriatic 
patients, stratified according to categories of MetS and ciga-
rette smoking.
Methods
Design and setting
This is a cross-sectional case–control observational study 
carried out at the Department of Clinical Medicine and Sur-
gery of the University of Naples Federico II (Italy), Unit 
of Endocrinology; from October 2015 to March 2017. The 
work has been carried out in accordance with the Code of 
Ethics of the World Medical Association (Declaration of 
Helsinki) for experiments involving humans, and it has 
been approved by the Ethical Committee of the University 
of Naples “Federico II” Medical School (n. 265/15). The 
purpose of the protocol was explained to both the patients 
and the controls, and written informed consent was obtained. 
The study was conducted without support from the pharma-
ceutical industry.
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Population study
The study has been conducted on 221 adult treatment-
naïve patients out of 359 unselected Caucasian subjects 
of both genders affected by psoriasis attending the Pso-
riasis Care Center of the Outpatient Clinic of the Sec-
tion of Dermatology, University of Naples Federico II. To 
improve the power of the study, we increased the homo-
geneity of the patient sample by including treatment-naïve 
adult patients only. In particular, exclusion criteria were 
the following:
1. diagnosis of psoriasis lasting < 6 months or subjects 
receiving any systemic treatment for psoriasis includ-
ing acitretin, ciclosporin, methotrexate, phototherapy or 
biologics for at least 3 months (52 patients) or diagnosis 
of pustular (five patients), erythrodermic (three patient) 
or psoriatic arthritis (18 patients);
2. pregnancy or lactation in the past 6  months (three 
patients);
3. history of excessive alcohol use according to the Diag-
nostic and Statistical Manual of Mental Disorders 
(DSM)-V diagnostic criteria (four patients);
4. neoplastic, metabolic, hepatic, and cardiovascular dis-
order or other concurrent medical illness (i.e., renal dis-
ease, and malabsorptive disorders) (nine patients);
5. occasional or current of use of medications (whether 
prescribed or over the counter) or energy drinks and 
beverages containing high concentrations of caffeine, 
such as Coca-Cola, red bull, guaranà, green tea, cacao, 
(23 patients);
6. decaffeinated coffee consumers (21 patients).
Two hundred twenty-one healthy subjects were chosen 
as controls among hospital volunteers and employees from 
the same geographical area. Controls were matched by age, 
sex and body mass index (BMI) and a full medical history, 
including drug use, was collected. The flow chart of study 
subjects is shown in Fig. 1.
Power size justification
The power size was calculated based on the following 
assumptions: 95% confidence interval (2-sided), and 221 
psoriatic patients. In addition, we assumed that the preva-
lence rate was 0.22 between the sample participants with 
consumption of coffee (99 psoriatic patients, > 3 cups coffee 
per day) and with the total population subjects (442 partici-
pants). Based on these assumptions, the calculated power 
size was 91%. The effect size calculation between < 3 cups 
coffee per day (122 patients) and > 3 cups coffee per day (99 
patients) in psoriatic patients sample was 0.44 by test for two 
proportion (Table 1).
Lifestyle habits
Lifestyle habits, including smoking and physical activity 
level, have been investigated by a standard questionnaire. 
Fig. 1  Flow chart of study 
design
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Subjects smoking at least one cigarette per day were con-
sidered current smokers, while former smokers were the 
subjects who stopped smoking at least one year before the 
interview. The remaining participants were defined as non-
current smokers. Physical activity levels were expressed 
according to whether the participant habitually engaged in 
at least 30 min/day of aerobic exercise (YES/NO).
Assessment of coffee consumption
The daily caloric intake and coffee consumption data were 
collected using a 7-day food diary record (Welch et al. 2001; 
Goulet et al. 2004). Information on coffee brewing (instant 
coffee or espresso by Italian coffeepot) and use of additives, 
such as cream, milk, etc., was obtained. These data were 
carried out during a face-to-face interview between the 
patient and a certified nutritionist. On day one of the diary, 
nutritionists trained to standardized protocols provided par-
ticipants with instructions on how to complete the diary at 
the health check and asked participants to recall the previ-
ous day’s intake. Participants prospectively completed the 
remaining 6 days and returned the records to the nutritionist. 
Data were processed using a commercial software (Terapia 
Alimentare Dietosystem® DS-Medica, http://www.dsmed 
ica.info). This database was able to calculate the total energy 
intake, expressed in kilocalories (kcal).
The coffee consumption was analyzed in two separate 
models: (1) coffee intake (consumers and non-consumers) 
and (2) daily servings of coffee (range 0–4 servings/day). 
In particular, the first category: non-consumers; the second 
category: 1 cup coffee per day; the third category: 2 cups 
coffee per day; the fourth category: 3 cups coffee per day; the 
fifth category: more than 4 cups of coffee per day.
Anthropometric measurements and blood pressure
All anthropometric measurements were taken with subjects 
wearing only light clothes and without shoes. In each sub-
ject, weight and height were measured to calculate the BMI 
[weight (kg) divided by height squared  (m2), kg/m2]. Height 
was measured to the nearest 1 cm using a wall-mounted 
stadiometer (Seca 711; Seca, Hamburg, Germany). Body 
weight was determined to the nearest 50 g using a calibrated 
balance beam scale (Seca 711; Seca, Hamburg, Germany). 
BMI was classified according to WHO’s criteria with nor-
mal weight: 18.5–24.9 kg/m2; overweight, 25.0–29.9 kg/
m2; grade I obesity, 30.0–34.9 kg/m2; grade II obesity, 
35.0–39.9 kg/m2; grade III obesity ≥ 40.0 kg/m2 (WHO 
2000). Waist circumference (WC) was measured to the clos-
est 0.1 cm using a non-stretchable measuring tape at the 
natural indentation or at a midway level between lower edge 
of the rib cage and iliac crest if no natural indentation was 
visible, according to the National Center for Health Statistics 
(NCHS) (NCHS 2014). In all individuals, systolic (SBP) and 
diastolic (DBP) blood pressure were measured three times, 
two min apart, with a random zero sphygmomanometer 
(Gelman Hawksley Ltd., Sussex, UK) after the subject had 
been sitting for at least 10 min. The average of the second 
and third reading was recorded.
Biochemical measurements
Samples were collected in study population between 8 and 
10 a.m. after an overnight fast of at least 8 h and stored at 
− 80 °C until processed. All biochemical analyses includ-
ing fasting plasma glucose, total cholesterol, triglycerides, 
were performed with a Roche Modular Analytics System 
in the Central Biochemistry Laboratory of our Institution. 
Low-density lipoprotein (LDL) and high-density lipopro-
tein (HDL) cholesterol were determined by direct method 
(homogeneous enzymatic assay for the direct quantitative 
determination of LDL and HDL cholesterol). C-reactive 
protein (CRP) levels were determined with a nephelometric 
assay with CardioPhase high-sensitive from Siemens Health-
care Diagnostics (Marburg, Germany).
Criteria to define metabolic syndrome
According to the National Cholesterol Education Program 
(NCEP)-Adult Treatment Panel (ATP III) definition, MetS is 
present if three or more of the following five criteria are met: 
WC over 102 and 88 cm (in male and female, respectively), 
blood pressure over 130/85 mmHg, fasting triglyceride level 
over 150 mg/dl, fasting HDL cholesterol level less than 40 
and 50 mg/dl (in male and female, respectively) and fasting 
glucose over 100 mg/dl (NCEP-ATP III 2001).
Psoriasis Area and Severity Index (PASI)
The classic Psoriasis Area and Severity Index (PASI) score 
assesses the extent and severity of psoriasis. The extent of 
psoriasis is measured by the body area involved and the sever-
ity of erythema, induration and desquamation of the plaques. 
The body area involved is the percentage of area involved in a 
Table 1  Power size justification
PR prevalent rate, α I type-error; 1 − β power size, ES effect size
Power size Effect size
Parameters Values Parameters Values
n 221 n (> 3 cups coffee per day) 99
PR 0.22 n (< 3 cups coffee per day) 122
α 0.05 α 0.05
1 − β 0.91 1 − β 0.91
ES 0.44
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particular body region. For calculating classic PASI, the body 
is divided into four body regions: head, upper extremities, 
trunk and lower extremities. These four body regions corre-
spond to approximately 10, 20, 30 and 40% of the total body 
surface area (BSA), respectively.
The PASI score is a validated and widely used tool for 
measuring psoriasis severity. The sum of the PASI scores for 
all four body regions is the total classic PASI score. The total 
classic PASI score ranges from 0 to 72 (Frediksson and Pet-
tersson 1978; Spuls et al. 2010). To prevent rate biases, the 
dermatologists who evaluated the PASI score were blinded to 
the design of the study.
Statistical analysis
Results are expressed as mean ± standard deviation (SD) or as 
median plus range according to variable distributions evalu-
ated by Kolmogorov–Smirnov test (p < 0.001). To correct for 
skewed distributions, CRP levels values were logarithmically 
transformed and back-transformed for presentation in tables. 
Differences between groups were analyzed by paired t test or 
Wilcoxon signed-rank test, when appropriate. A Chi-square 
(χ2) test was used to test the significance of differences in fre-
quency distribution. Differences in coffee consumption (yes/
no) and PASI score among smoking and MetS categories, were 
analyzed by unpaired t test for independent samples. When 
more than two groups were compared, analyses of variance 
(ANOVA) or Kruskal–Wallis test were performed, as appro-
priate, followed by Bonferroni post hoc analysis. Proportional 
Odds Ratio (OR) models, 95% Interval Confidence (IC), and 
Akaike Information Criterion (AIC), were performed to assess 
the association among quantitative variables (consumer and 
non-consumers of coffee). Multinomial logistic regression, 
probability, OR, IC and AIC, was performed to model the rela-
tionship between the PASI score and the five groups of daily 
servings of coffee (range 0–4 servings/day). In these analyses, 
we entered only those variables that had a p value < 0.05 in 
the univariate analysis. To avoid multicollinearity, variables 
with a variance inflation factor (VIP) > 10 were excluded. Val-
ues ≤ 5% were considered statistically significant. Data were 
stored and analyzed using the MedCalc® package (Version 
12.3.0 1993–2012 MedCalc Software bvba, MedCalc Soft-
ware, Mariakerke, Belgium). Proportional odds model and 
multinomial logistic regression were carried out using the R 
Project for Statistical Computing 2014 (http://www.R-proje 
ct.org).
Results
The study population consisted of 221 psoriatic patients, 
aged 21–59 years (57.5%, 127 males). Their mean value 
of PASI score was 8.13 ± 6.64. All case patients completed 
the 7-day food diary record. Mean total energy intake was 
2747.39 ± 544.26. Table  2 reports the anthropometric 
measurements, the clinical characteristics and lifestyle 
habits of the case patients and the subjects matched for 
age, sex and BMI, serving as control group. As expected, 
psoriatic patients presented worse anthropometric meas-
urements and metabolic profile, and higher CRP levels 
compared to the control group (p < 0.001). Among pso-
riatic patients, there were more smokers than in con-
trols, whereas there were no differences in their physical 
activity. Figure 2 shows that the prevalence of the single 
metabolic risk factors and MetS were significantly higher 
among case patients than controls (p < 0.001).
The coffee intake in two groups is shown in Fig. 3. No 
significant differences were found in the coffee intake 
between case patients and control group; in particular, cof-
fee drinkers were 190 (86.0%) among case patients vs 176 
among controls (79.6%); χ2 = 2.69, p = 0.101; in addition, 
the coffee preparation method was not different, as in both 
groups, the coffee drinkers did not consume instant coffee 
or used additives, such as cream, milk, etc. Considering 
the daily servings of coffee in psoriatic patients, the major-
ity of psoriatic patients consumed 3 cups coffee per day 
(77 patients, 34.8%) (Fig. 4).
Table  3 summarizes the anthropometric measure-
ments and clinical characteristics stratified according 
to the daily servings of coffee. The best anthropometric 
measurements and metabolic profile, in particular a lower 
number of Mets parameters (p < 0.001), were observed in 
subgroup of psoriatic patients consuming 3 cups coffee 
per day. In Fig. 5 were reported the PASI score and CRP 
levels in psoriatic patients grouped according to coffee 
intake or daily servings of coffee. The coffee consumers 
have lower PASI score (7.02 ± 6.05 vs 14.90 ± 6.13) and 
CRP levels (3.92 ± 4.23 vs 5.75 ± 5.99 ng/ml) compared 
to non-consumers (p < 0.001). Again, the lowest PASI 
score (2.89 ± 2.06) and CRP levels (2.49 ± 3.22 ng/ml) 
were found among psoriatic patients consuming 3 cups 
coffee per day (n = 77), while the highest PASI score 
(19.76 ± 5.15) and CRP levels (8.60 ± 5.76 ng/ml) were 
found among those drinking ≥ 4 cups per day.
In Table 4, mean PASI score values were reported accord-
ing to coffee intake, smoking and MetS categories. Across 
all categories, coffee drinkers showed an overall lower PASI 
score compared to non-consumers, with the lowest PASI 
score in the category no smoking and no MetS (p < 0.001). 
In Table 5, mean of PASI score values were shown accord-
ing to the daily servings of coffee, smoking and MetS cat-
egories. Across all daily servings of coffee, in the category 
no smoking and no MetS, the psoriatic patients drinking 3 
cups coffee per day showed the lowest PASI score, while 
case patients drinking ≥ 4 cups per day have the highest 
PASI score.
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Correlation studies
In Table 6 was reported a bivariate proportional odds ratio 
model performed to assess the association of coffee intake 
with anthropometric measures, metabolic and inflamma-
tory profile, and lifestyle habits. Coffee intake was associ-
ated positively with HDL cholesterol and physical activity, 
and negatively with triglycerides, inflammatory profile, 
MetS presence, and smoking. Table 7 shows the multi-
nomial logistic regression model performed to assess the 
association among five different servings of coffee con-
sumption with the PASI score adjusted for total energy 
intake. Grouping the case patients according to smoking 
and MetS, the best odds of PASI score was observed in 
those drinking 3 cups coffee per day with no smoking and 
without MetS, independently for total energy intake (OR 
74.8, p < 0.001).
Discussion
The present study evidenced a negative association between 
coffee intake, MetS prevalence and clinical severity of pso-
riasis in a sample of treatment-naïve psoriatic patients. 
According to the current literature supporting the inflam-
matory link between psoriasis and with MetS, we confirmed 
that among psoriatic patients, there was a greater presence of 
MetS compared to age, sex and BMI-matched control group 
(Rodríguez-Zúñiga and García-Perdomo 2017). As novel 
findings, we evidenced that psoriatic patients who consumed 
coffee presented lower clinical severity and better anthro-
pometric measurements and metabolic profile compared to 
non-consumers, independently of gender and total energy 
intake calculated by the 7-day food diary record. Of inter-
est is that stratifying the study group of psoriatic patients 
according to the daily servings of coffee, smoking habits 
Table 2  Anthropometric 
measurements, clinical 
characteristics and lifestyle 
habits of the case patients and 
the subjects matched for age, 
sex and BMI, serving as control 
group
The psoriatic patients exhibited statistically significant differences compared to controls for BMI, WC, 
blood pressure, metabolic profiles, CRP levels and smoking habit
Results are expressed as mean ± SD or as median plus range according to variable distributions evaluated 
by Kolmogorov–Smirnov test
a CRP levels was logarithmically transformed and back-transformed for presentation in table. Differences 
between groups were analyzed by paired t test or Wilcoxon signed-rank test, when appropriate. The Chi-
square (χ2) test was used to determine the significance of differences in physical activity and smoking habit 
between the two groups. A p value in bold type denotes a significant difference (p < 0.05)
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, 
HDL high-density lipoprotein, LDL low-density lipoprotein, CRP C-reactive protein
Parameters Psoriatic patients, n = 221 Control group, n = 221 p values
Age (years) 37.0 (21.0–59.0) 36.0 (20.0–49.0) 0.508
Gender, males (n, %) 127, (57.5%) 127, (57.5%) χ2 = 0.009, p = 0.923
BMI (kg/m2) 30.4 ± 5.8 29.7 ± 7.3 0.295
 Normal weight (n, %) 43, 19.5% 67, 30.3% χ2 = 6.40, p = 0.011
 Overweight (n, %) 68, 30.8% 63, 28.5% χ2 = 0.17, p = 0.677
 Obesity I (n, %) 64, 29.0% 46, 20.8% χ2 = 3.49, p = 0.062
 Obesity II (n, %) 36, 16.3% 19, 8.6% χ2 = 5.32, p = 0.021
 Obesity III (n, %) 10, 4.5% 26, 11.8% χ2 = 6.80, p = 0.009
WC (cm) 108.0 (69.0–156.0) 97.0 (61.0–147.0) < 0.001
SBP (mmHg) 130.0 (100.0–165.0) 120.0 (90.0–165.0) 0.003
DBP (mmHg) 80.0 (50.0–100.0) 75.0 (50.0–100.0) < 0.001
Fasting glucose (mg/dl) 104.0 (65.0–199.0) 94.0 (59.0–198.0) 0.002
Total cholesterol (mg/dl) 205.6 ± 50.0 190.9 ± 54.4 0.003
HDL cholesterol (mg/dl) 39.0 (22.0–79.0) 44.0 (26.0–71.0) 0.007
LDL cholesterol (mg/dl) 135.7 ± 45.9 123.1 ± 51.2 0.008
Triglycerides (mg/ml) 163.3 ± 75.4 141.3 ± 41.9 < 0.001
CRP levels (ng/ml)a 2.8 (0.10–30.24) 0.9 (0.10–3.98) < 0.001
Physical activity
 Sedentary (n, %) 154, 69.7% 149, 67.4% χ2 = 0.17
p = 0.682 Moderate (n, %) 67, 30.3% 72, 32.6%
Smoking
 Yes (n, %) 126, 57.0% 97, 43.9% χ2 = 7.09
p = 0.008 No (n, %) 95, 43.0% 124, 56.1%
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and presence/absence of MetS, the category of patients con-
suming of 3 cups of coffee per day, no smokers and with-
out MetS, presented the lowest PASI score compared to the 
other categories, independently of total energy intake.
Psoriasis is a common, chronic, immune-mediated skin 
disease with systemic pro-inflammatory activation, where 
both environmental and genetic factors contribute to its 
pathogenesis (Ahdout et al. 2012). The treatment of envi-
ronmental modifiable risk factors, such as diet and nutrition, 
and modulation of the systemic inflammatory response are 
important therapeutic goals in the integrated management of 
psoriatic patients (Trojacka et al. 2015; Balato et al. 2015b). 
Among the risk factors for psoriasis, evidence is accumu-
lating that nutrition plays a major role per se in psoriasis 
pathogenesis and dietary factors can affect both drug’s phar-
macokinetics and pharmacodynamics (Kim and Lee 2013). 
Single food components have been suggested to play a role 
in etiology and pathogenesis of psoriasis (Wolters 2006; 
Millsop et al. 2014).
Coffee is among the most widely consumed pharmaco-
logically active beverages, and its consumption has become 
a regular part of daily life worldwide. Coffee is one of the 
major contributors of caffeine to the diet (Mitchell et al. 
2015). Caffeine, which represents no more than 1% of the 
Fig. 2  Frequency of metabolic risk factors and prevalence of the 
MetS in psoriatic patients and control group. The psoriatic patients 
exhibited statistically significant differences in all the MetS param-
eters compared to controls: WC (71.5 vs 51.1%; χ2 = 18.5, p < 0.001), 
SBP/DBP (43.9 vs 28.5%; χ2 = 10.7, p = 0.001), triglycerides (59.7 
vs 25.8%; χ2 = 50.6, p < 0.001), HDL-C (62.0 vs 30.8%; χ2 = 42.7, 
p < 0.001); fasting glucose (59.3 vs 43.4%; χ2 = 10.5, p = 0.002) and 
MetS presence/absence (64.3 vs 31.2%; χ2 = 47.0, p < 0.001), respec-
tively. The MetS is defined according to the NCEP ATP III definition 
(Expert Panel on Detection 2001). Results are expressed as percent-
age. The Chi-square (χ2) test was used to determine the significance 
of differences in the frequencies between the two groups. A p value 
in bold type denotes a significant difference (p < 0.05). WC waist cir-
cumference, SBP systolic blood pressure, DBP diastolic blood pres-
sure, HDL-C high-density lipoprotein cholesterol, MetS metabolic 
syndrome, NCEP ATP III National Cholesterol Education Program 
Adult Treatment Panel
Fig. 3  Coffee intake in psoriatic patients and control group. No sig-
nificant differences were found in the coffee intake between case 
patients and control group. Coffee drinkers were 190 (86.0%) among 
case patients vs 176 among controls (79.6%); χ2 = 2.69, p = 0.101. 
Results are expressed as percentage. The Chi-square (χ2) test was 
used to test the significance of differences in the frequency of coffee 
consumers between the two groups. A p value in bold type denotes a 
significant difference (p < 0.05)
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total coffee composition, is a biologically active natural 
metabolite with widely recognized therapeutic effects (Mon-
tagnana et al. 2012). Caffeine exerts a number of biologi-
cal effects, acting also on inflammation and immune sys-
tem (Festugato 2011; Hall et al. 2015). Caffeine is able to 
reduce the migration of monocytes and neutrophils, blood 
cells closely involved in mediating of inflammation and 
activation of adaptive immune system (Sharif et al. 2017). 
This interesting role of caffeine in immunosuppression, and 
specifically in autoimmune diseases, is also explained by the 
inhibition of the release of pro-inflammatory cytokines and 
Th1/Th2 cell proliferation. At high doses, caffeine is able to 
Fig. 4  Daily servings of coffee 
in psoriatic patients. The daily 
servings of coffee consump-
tion (range 0–4 servings/
day) were analyzed. The first 
category: non-consumers; the 
second category: 1 cup coffee 
per day; the third category: 2 
cups coffee per day; the fourth 
category: 3 cups coffee per day; 
the fifth category: more than 4 
cups of coffee per day. Results 
are expressed as percentage. 
The majority of the 190 coffee 
drinking patients (77 patients) 
consumed 3 cups coffee per day 
(34.8%)
Table 3  Anthropometric measures and metabolic profile of psoriatic patients according to daily servings of coffee (0–4 servings/day)
The best anthropometric measurements and metabolic profile, in particular a lower number of MetS parameters (p < 0.001) were observed in the 
subgroup of psoriatic patients consuming 3 cups coffee per day
Results are expressed as mean ± SD or as median plus range according to variable distributions evaluated by Kolmogorov–Smirnov test. Differ-
ences between groups were analyzed by ANOVA or Kruskal–Wallis test, when appropriate. A p value in bold type denotes a significant differ-
ence (p < 0.05)
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein, LDL 
low-density lipoprotein, MetS metabolic syndrome
Parameters Daily servings of coffee consumption (cups per day)
0 cups 1 cup 2 cups 3 cups ≥ 4 cups p value
n = 31, 14.0% n = 32, 14.5% n = 59, 26.7% n = 77, 34.8% n = 22, 10.0%
Age (years) 36.0 (21.0–50.0) 39.0 (23.0–50.0) 37.0 (24.0–59.0) 36.0 (21.0–59.0) 36.5 (21.0–54.0) 0.449
BMI (kg/m2) 30.9 ± 5.4 30.8 ± 5.6 29.3 ± 4.6 29.4 ± 6.1 35.5 ± 5.7 < 0.001
WC (cm) 109.0 (72.0–149.0) 109.5 (81.0–149.0) 105.0 (69.0–142.0) 98.0 (69.0–142.0) 134.5 (106.0–156.0) < 0.001
SBP (mmHg) 135.0 (100.0–150.0) 135.0 (100.0–150.0) 125.0 (100.0–155.0) 120.0 (110.0–165.0) 140.0 (110.0–160.0) < 0.001
DBP (mmHg) 80.0 (60.0–100.0) 85.0 (60.0–100.0) 80.0 (50.0–95.0) 75.0 (60.0–95.0) 85.0 (60.0–100.0) 0.002
Fasting glucose (mg/dl) 104.0 (70.0–196.0) 112.5 (68.0–190.0) 101.0 (65.0–149.0) 102.0 (68.0–197.0) 121.5 (71.0–199.0) 0.024
Total cholesterol (mg/
dl)
213.4 ± 50.6 207.5 ± 42.7 207.1 ± 44.9 188.6 ± 46.3 247.0 ± 59.9 < 0.001
HDL cholesterol (mg/
dl)
35.0 (24.0–63.0) 38.5 (22.0–79.0) 43.0 (23.0–64.0) 46.0 (26.0–79.0) 31.5 (24.0–51.0) < 0.001
LDL cholesterol (mg/
dl)
139.4 ± 47.6 139.6 ± 41.3 137.9 ± 42.6 116.9 ± 43.0 180.0 ± 42.0 < 0.001
Triglycerides (mg/ml) 194.5 ± 68.4 158.9 ± 64.7 155.4 ± 75.6 137.9 ± 68.0 236.0 ± 68.0 < 0.001
MetS (number param-
eters)
3.4 ± 1.2 3.6 ± 1.1 2.7 ± 1.4 2.2 ± 1.5 4.2 ± 0.8 < 0.001
Energy intake (kcal) 2739.9 ± 504.8 2720.3 ± 523.6 2629.9 ± 513.9 2757.9 ± 550.0 3075.6 ± 597.5 0.027
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inhibit the Cyclic Adenosine MonoPhosphate (cAMP) phos-
phodiesterase, resulting in increased cAMP levels, which 
acts as immunomodulator and stimulates the release of anti-
inflammatory cytokines (Sharif et al. 2017), in particular in 
immune cells (Festugato 2011). In addition, caffeine acts 
as a receptor antagonist of adenosine (Gökcen and Şanlier 
2017). However, coffee is a complex mixture of chemicals 
and, beyond caffeine, it also contains thousands of differ-
ent chemicals, including carbohydrates, lipids, nitrogenous 
compounds, vitamins, minerals, alkaloids, and phenolic 
compounds with different functional properties (Spiller 
1984; Bae et al. 2014). Several mechanisms have been pro-
posed to explain the role of bioactive compounds of coffee 
on systemic inflammation. Coffee habitual consumption, 
in human and in animal models, can reduce the levels of 
interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and 
CRP levels; on the other hand, it can increase anti-inflam-
matory markers, such as adiponectin, IL-4 and IL-10 levels 
(Akash et al. 2014). Probably, this anti-inflammatory effect 
might be specifically linked to the polyphenols contained 
in coffee. These polyphenols, in particular chlorogenic acid 
and its metabolites, are able to inhibit in vitro the activa-
tion of NF-κB in a dose-dependent manner, acting against 
the oxidative stress due to ROS accumulation and inhibiting 
pro-inflammatory mediators synthesis and release (in par-
ticular, TNF-α, IL-1β and -6, and Interferon (INF)-γ), while 
caffeic acid causes a decreasing in nitrite levels and inhibi-
tion of inflammation pathways (Hall et al. 2015). Interest-
ingly, in coffee specific polysaccharides are present (such as 
arabinogalactan proteins) which act as immunomodulatory 
agents, stimulating splenocytes and peritoneal macrophages 
proliferation, resulting in improving dermatitis and allergic 
Fig. 5  The PASI score and CRP levels in psoriatic patients grouped 
according to coffee intake (yes/no) and daily servings of coffee (range 
0–4 servings/day). The coffee consumers (n = 190) have lower PASI 
score (7.02 ± 6.05 vs 14.90 ± 6.13) and CRP levels (3.92 ± 4.23 vs 
5.75 ± 5.99  ng/ml) compared to non-consumers (n = 31) (p < 0.001). 
The lowest PASI score (2.89 ± 2.06) and CRP levels (2.49 ± 3.22 ng/
ml) were found among psoriatic patients consuming 3 cups coffee per 
day (n = 77), while the highest PASI score (19.76 ± 5.15) and CRP 
levels (8.60 ± 5.76 ng/ml) were found among those drinking ≥ 4 cups 
per day. One cup coffee per day (n = 32): PASI score (9.45 ± 3.44) and 
CRP levels (3.84 ± 4.41 ng/ml); 2 cups coffee per day (n = 59): PASI 
score (6.34 ± 3.16) and CRP levels (4.06 ± 3.93  ng/ml). Results are 
expressed as mean ± SD. CRP levels was logarithmically transformed 
and back-transformed for presentation in figure. Differences between 
two groups were analyzed by paired t test, while the differences 
among more than two groups were analyzed by ANOVA, followed by 
Bonferroni post hoc analysis. A p value in bold type denotes a signifi-
cant difference (p < 0.05). PASI Psoriasis Area Severity Index; CRP 
C-reactive protein, NF-κB nuclear factor kappa B, ROS reactive oxy-
gen species, MetS metabolic syndrome, BMI body mass index, kcal 
kilocalories, WC waist circumference, NCHS National Center for 
Health Statistics, SBP systolic blood pressure, DBP diastolic blood 
pressure, LDL low-density lipoprotein, HDL high-density lipopro-
tein, CRP C-reactive protein, NCEP-ATP III National Cholesterol 
Education Program-Adult Treatment Panel, PASI Psoriasis Area and 
Severity Index, BSA body surface area, SD standard deviation, OR 
odds ratio, IC interval confidence, AIC Akaike information criterion, 
cAMP Cyclic Adenosine MonoPhosphate, IL interleukin, TNF tumor 
necrosis factor, INF interferon
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reactivity (Gökcen and Şanlier 2017). As support for its anti-
inflammatory effects, an in vitro study suggested that coffee 
extract was able to exert anti-inflammatory and immunosup-
pressant activity (Gökcen and Şanlier 2017).
No previous studies have investigated in psoriatic patients 
the association between daily servings of coffee and clini-
cal severity of the disease in treatment-naïve patients, 
after adjustment for known confounders, such as smoking 
habit and MetS. Out of 3 studies evaluating the association 
between coffee consumption and psoriasis, 2 of them used 
these variables as dichotomous ones (yes/no), thus providing 
only a rough estimate of coffee intake and psoriasis (Duffy 
et al. 1993; Swanson et al. 2007); in addition, the clinical 
severity of psoriasis was not taken into consideration. Coffee 
consumption has often been measured by items on dietary 
questionnaires and interviews and, with respect to meas-
uring coffee consumption, studies have noted sufficiently 
repeatability (Sääksjärvi et al. 2010). By contrast, 7-day food 
record, considered the “gold standard” of self-administered 
food frequency questionnaires, allows a more accurate meas-
urement of the real total energy intake, and of single foods 
and beverages, such as coffee, compared to those obtained 
by retrospective food frequency questionnaires (Thompson 
and Subar 2013; Hoidrup et al. 2002). In the third study, Li 
et al. (2012) reported that the risk of psoriasis was moder-
ately elevated with increasing coffee consumption in an age-
adjusted model, although this trend became not significant 
after adjusting for smoking, whereas the decaffeinated cof-
fee was not significantly associated with this risk. Although 
these authors provided a detailed description of caffeine 
intake, which was calculated according to the method of the 
US Department of Agriculture food composition data, in 
this study all the caffeinated beverages were included, with a 
possible misleading effect due to their high sugar and energy 
ratio (Li et al. 2012). In addition, in this study, the diagnosis 
of psoriasis, although confirmed using the Psoriasis Screen-
ing Tool questionnaire, was ascertained by self-report on 
Table 4  Differences of clinical severity of psoriasis according to cof-
fee intake, smoking and MetS categories
Across all categories, coffee drinkers showed an overall lower PASI 
score compared to non-consumers, with the lowest PASI score 
in the category no smoking and no MetS. Results are expressed as 
mean ± SD according to variable distributions evaluated by Kolmogo-
rov–Smirnov test. Differences between two groups were analyzed by t 
test for independent samples. A p value in bold type denotes a signifi-
cant difference (p < 0.05)
PASI Psoriasis Area Severity Index, MetS metabolic syndrome, SD 
standard deviation
Parameters PASI score
n Mean ± SD p value
Smoking
 Coffee consumption 103 10.8 ± 5.9 < 0.001
 No coffee consumption 23 17.6 ± 4.7
No smoking
 Coffee consumption 87 2.6 ± 1.7 < 0.001
 No coffee consumption 8 7.2 ± 0.9
MetS
 Coffee consumption 116 9.1 ± 6.4 < 0.001
 No coffee consumption 26 15.7 ± 6.2
No MetS
 Coffee consumption 74 3.8 ± 3.5 < 0.001
 No coffee consumption 5 10.6 ± 3.6
No smoking/no MetS
 Coffee consumption 51 1.9 ± 1.3
 No coffee consumption 3 8.1 ± 0.9 < 0.001
Table 5  Differences of clinical severity of psoriasis according to the 
daily servings of coffee, smoking and MetS categories
Results are expressed as mean ± SD, according to variable distribu-
tions evaluated by Kolmogorov–Smirnov test. Differences between 
groups were analyzed by ANOVA. A p value in bold type denotes a 
significant difference (p < 0.05)
Across all daily servings of coffee, in the category no smoking and 
no MetS, the psoriatic patients drinking 3 cups coffee per day showed 
the lowest PASI score, while case patients drinking ≥ 4 cups per day 
have the highest PASI score
PASI Psoriasis Area Severity Index, MetS metabolic syndrome, SD 
standard deviation
Parameters n PASI score p values
Smoking 12.0 ± 6.2 < 0.001
 1 cup coffee per day 23 10.9 ± 3.0 –
 2 cups coffee per day 37 8.4 ± 1.6 –
 3 cups coffee per day 21 5.5 ± 1.7 –
 ≥ 4 cups coffee per day 22 19.8 ± 5.2 –
No smoking 3.0 ± 2.1 < 0.001
 1 cup coffee per day 9 5.8 ± 0.4 –
 2 cups coffee per day 22 2.8 ± 1.6 –
 3 cups coffee per day 56 1.9 ± 1.1 –
 ≥ 4 cups coffee per day 0 – –
MetS 10.3 ± 6.8 < 0.001
 1 cup coffee per day 27 9.6 ± 3.5 –
 2 cups coffee per day 38 6.9 ± 2.8 –
 3 cups coffee per day 30 3.9 ± 2.4 –
 ≥ 4 cups coffee per day 21 19.8 ± 5.3 –
No MetS 4.2 ± 3.9 < 0.001
 1 cup coffee per day 5 8.6 ± 3.5
 2 cups coffee per day 21 5.2 ± 3.4
 3 cups coffee per day 47 2.2 ± 1.5
 ≥ 4 cups coffee per day 1 19.6
No smoking/No MetS < 0.001
 1 cup coffee per day 0 –
 2 cups coffee per day 11 2.3 ± 1.4
 3 cups coffee per day 40 1.7 ± 1.1
 ≥ 4 cups coffee per day 0 –
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questionnaires, and there were no indications on the clinical 
severity of the disease or medication use (treatment-naïve/
on treatment). Interestingly, the authors also reported that 
coffee improved the efficacy of psoriasis pharmacological 
treatment, such as methotrexate and sulfasalazine (Li et al. 
2012).
It is, however, important to consider that the cross-sec-
tional studies reported have examined the effects of long-
term coffee consumption, while the effect observed in the 
initial consumption of coffee, and the effect following recur-
ring consumption could be different. In particular, during 
the acute inflammatory state, caffeine had been reported 
to exert a pro-inflammatory activity, resulting in increased 
inflammatory markers levels, including TNF-α and β, IL-6 
and INF-γ. Interestingly, these pro-inflammatory cytokines, 
exert in psoriasis a clear mitogen activity for keratinocytes 
(Festugato 2011). Nevertheless, although several studies 
reported pro-inflammatory effects of caffeine, others under-
lined a converse effect, anti-inflammatory by increasing 
IL-10 (Sharif et al. 2017) and inhibiting TNF-α production 
in vitro (Hall et al. 2015). As a support for these findings, 
the use of topical formulation of caffeine on plaque psoriasis 
resulted in a significant improvement in psoriasis area and 
severity index in a double-blinded placebo controlled study 
which demonstrated (Vali et al. 2005). In this respect, our 
study evidenced that the coffee intake exerted a beneficial 
effect on psoriasis clinical severity and this effect was also 
dose-related. In fact, we found out that CRP levels and PASI 
score decreased as much as the coffee’s daily consumption 
increases. However, this relationship was lost when the sub-
jects took more than 4 cups daily and this could be explained 
by a possible pro-inflammatory effect of excessive coffee 
intake, as previously reported (Lopez-Garcia et al. 2006; 
Zampelas et al. 2004; Corrêa et al. 2013). In particular, 
Zampelas et al. (2004), in a cross-sectional survey enrolled 
a large number of adults aimed to investigate the associa-
tion between coffee consumption and inflammatory markers, 
and found that coffee consumption < 200 ml/day was related 
to higher plasma concentrations of IL-6, CRP levels, and 
TNF-α, lending support to the hypothesis that compounds 
in this beverage could contribute to increased inflammation 
(Zampelas et al. 2004). This relation could explain, in part, 
the effect of increased coffee consumption on the clinical 
severity of psoriasis that we observed in our study.
We are aware that there are some limitations in the current 
study. First, the cross-sectional nature of this study did not 
allow determine whether any cause-and-effect relationship 
exists between coffee intake and clinical severity of psoriasis. 
Second, in this study, we did not include the psoriatic patients 
who consumed the decaffeinated coffee. Therefore, we cannot 
determine the relative contribution of caffeine or polyphenols 
to our results. Third, the sample size is relatively small and a 
larger group of patients would have been more informative. 
However, for greater statistical accuracy, we calculated the 
power size justification, which was of 91% and the effect size 
calculation between < 3 cups coffee per day and > 3 cups cof-
fee per day of coffee in psoriatic patients sample was 0.44 by 
test for two proportion. Further strengths of this study include 
that the diagnosis of psoriasis was not self-reported, but clini-
cally evaluated using the PASI score by an experienced der-
matologist, and the possible interference of the anti-psoriatic 
agents was controlled by including only treatment-naïve 
patients; in addition, the nutritional status was evaluated using 
the 7-day food diary record, by an experienced nutritionist. 
This method, which is considered as the “gold standard” in 
Table 6  Bivariate proportional odds ratio model performed to assess 
the association of coffee intake with anthropometric measures, meta-
bolic and inflammatory profile, and lifestyle habits
Coffee intake was associated positively with HDL cholesterol and 
physical activity, and negatively with triglycerides, inflammatory pro-
file, MetS presence, and smoking. Proportional odds model were car-
ried out using the R Project for Statistical Computing 2014 (http://
www.R-proje ct.org)
OR odds ratio, CI confidence interval, AIC Akaike information cri-
terion, BMI body mass index, WC waist circumference, SBP systolic 
blood pressure, DBP diastolic blood pressure, HDL high-density lipo-
protein, LDL low-density lipoprotein, CRP C-reactive protein, PASI 
Psoriasis Area Severity Index, MetS metabolic syndrome
a CRP levels was logarithmically transformed and back-transformed 
for presentation in table
Parameters OR p value 95% CI AIC
Gender 0.272 182.01
 Male 0.65 0.26–1.04
 Female 1.53 1.14–1.92
Age (years) 1.02 0.370 0.99–1.04 182.40
BMI (kg/m2) 0.98 0.596 0.98–1.05 182.93
WC (cm) 0.99 0.681 0.98–1.00 183.04
SBP (mmHg) 0.98 0.418 0.97–1.00 182.56
DBP (mmHg) 1.00 0.825 0.98–1.02 183.16
Fasting glucose (mg/dl) 0.99 0.049 0.98–1.01 182.44
Total cholesterol (mg/dl) 0.99 0.046 0.99–1.00 182.32
HDL cholesterol (mg/dl) 1.04 0.047 1.02–1.06 178.82
LDL cholesterol (mg/dl) 0.99 0.036 0.99–1.01 176.24
Triglycerides (mg/ml) 0.99 0.016 0.99–1.00 177.58
CRP levels (ng/ml)a 0.92 0.044 0.89–0.96 179.43
PASI score 0.85 < 0.001 0.82–0.88 150.31
MetS
 Yes 0.30 0.018 2.81–3.83 176.48
 No 3.31 0.21–0.81
Physical activity 0.007 166.27
 Sedentary 0.06 14.94–16.99
 Moderate 15.96 0.96–1.09
Smoking 0.041 178.65
 Yes 2.42 1.99–2.86
 No 0.41 0.02–0.85
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validation studies of different types of self-administered food 
frequency questionnaires, allowed to better characterize the 
coffee intake as daily servings and total energy intake. Moreo-
ver, in spite of the wide variability in the coffee preparation 
methods reported across the other studies, and consequently in 
caffeine content, all the participants in this study have the same 
geographical origin and consumed coffee in the Italian style.
Conclusions
Caffeine is the most frequently consumed pharmaco-
logically active substance globally. Because of its wide 
consumption in the population, the evaluation of the 
anti-inflammatory effect of coffee on clinical severity 
Table 7  Multinomial logistic 
regression model performed to 
assess the association among 
five different servings of coffee 
(0 to ≥ 4 cups coffee per day) 
with the PASI score, after 
adjusting for the total energy 
intake
Grouping the case patients according to smoking and MetS, the best odds of PASI score was observed 
in those drinking 3 cups coffee per day no-smoking, independently for total energy intake (OR 74.8, 
p < 0.001)
A p value in bold type denotes a significant difference (p < 0.05). Multinomial logistic regression were car-
ried out using the R Project for Statistical Computing 2014 (http://www.R-proje ct.org)
PASI Psoriasis Area Severity Index, OR odds ratio, AIC Akaike information criterion, CI confidence inter-
val, MetS metabolic syndrome
Parameters n Probability p value OR AIC 95% CI
Smoking 126
 0 cup coffee per day 23 (intercept) (intercept) (intercept) 250.66
1 cup coffee per day 23 − 0.45 < 0.001 0.61 0.47–0.75
 2 cups coffee per day 37 − 0.63 < 0.001 1.01 0.85–1.17
 3 cups coffee per day 21 − 0.83 < 0.001 1.81 1.57–2.06
 ≥ 4 cups coffee per day 22 0.07 < 0.001 0.07 0.01–0.13
No smoking 95
 0 cup coffee per day 8 (intercept) (intercept) (intercept) 107.53
 1 cup coffee per day 9 − 0.95 < 0.001 9.71 9.70–9.72
 2 cups coffee per day 22 − 0.95 < 0.001 74.2 74.28–74.30
 3 cups coffee per day 56 − 0.95 < 0.001 74.8 74.80–74.82
 ≥ 4 cups coffee per day – – – – –
MetS 142
 0 cup coffee per day 26 (intercept) (intercept) (intercept) 322.38
1 cup coffee per day 27 − 0.25 < 0.001 0.28 0.21–0.36
 2 cups coffee per day 38 − 0.39 < 0.001 0.49 0.41–0.58
 3 cups coffee per day 30 − 0.59 < 0.001 0.91 0.77–1.05
 ≥ 4 cups coffee per day 21 − 0.13 < 0.001 0.12 0.07–0.18
No MetS 79
 0 cup coffee per day 5 (intercept) (intercept) (intercept) 132.83
 1 cup coffee per day 5 − 0.18 < 0.001 0.20 0.01–0.39
 2 cups coffee per day 21 − 0.40 < 0.001 0.52 0.35–0.69
 3 cups coffee per day 47 − 0.65 < 0.001 1.05 0.85–1.25
 ≥ 4 cups coffee per day 1 – – – –
No smoking/No MetS 54
 0 cup coffee per day 3 (intercept) (intercept) (intercept) 225.29
 1 cup coffee per day – – – – –
 2 cups coffee per day 11 − 0.47 0.004 0.57 0.44–0.69
 3 cups coffee per day 40 − 0.72 < 0.001 1.12 0.96–1.28
 ≥ 4 cups coffee per day – – – – –
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of psoriasis, whose metabolic risk increases along with 
its clinical severity, could be of great importance from a 
public health perspective. The novel association between 
coffee consumption, MetS prevalence and clinical severity 
of psoriasis suggests that a growing cooperation among 
nutritionists, endocrinologists and dermatologists might 
provide a combination key in the complex management of 
the psoriatic patients and may encourage further studies to 
evaluate the effects of the changes in coffee intake on pso-
riasis. Future studies comparing long-term consumption 
of caffeinated coffee and decaffeinated coffee containing 
bioactive components, such as polyphenols, on clinical 
severity in psoriatic patients may be of interest.
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